ANGLE and Myriad Genetics Partner to Explore Blood-Based Genomic Testing
In a move that could reshape the landscape of cancer diagnostics, ANGLE has announced a strategic collaboration with Myriad Genetics to evaluate whether circulating tumour cell (CTC) DNA extracted from blood can be effectively integrated into Myriad’s existing tissue-based diagnostic assays.
Pioneering a Less Invasive Approach
The joint project will see ANGLE’s research and development team process blood samples from cancer patients using its FDA-approved Parsortix system.
This technology captures intact cancer cells circulating in the bloodstream, which can then be analysed for valuable genetic information. The results will be directly compared with matched tissue samples processed through Myriad Genetics’ well-established diagnostic platforms.
By shifting from traditional tissue biopsies to a simple blood test, researchers aim to make genomic testing more accessible and less invasive. Such an approach could significantly reduce the barriers patients face when undergoing biopsies, while also speeding up the delivery of actionable insights for oncologists and care teams.
Industry Leaders Joining Forces
ANGLE’s CEO expressed enthusiasm for the collaboration, stating that the company is delighted to be working with Myriad Genetics on a project that has the potential to extend tissue-based tests into a straightforward blood draw.
They also highlighted the possibility of transforming access to genomic data, enabling broader use of precision medicine in oncology.
Meanwhile, Myriad Genetics will bring its deep expertise in tissue-based diagnostics to the partnership, ensuring rigorous comparisons and a clear evaluation of whether CTC-based blood testing can deliver equivalent or complementary insights.
Building on Proven Technology
The Parsortix system is no stranger to clinical validation. Not only has it secured approval from the US Food and Drug Administration (FDA), but its performance is also supported by more than 110 peer-reviewed publications.
Its ability to capture intact cancer cells, rather than fragments of DNA alone, positions it uniquely for potential breakthroughs in liquid biopsy applications.
While further details of the agreement between ANGLE and Myriad Genetics remain confidential, both companies have signalled their intent to expand the role of liquid biopsy in precision oncology, making it a powerful tool in guiding treatment decisions.
Conclusion
This collaboration marks an important step forward in the ongoing shift from traditional biopsies to liquid biopsy techniques.
By combining ANGLE’s cutting-edge Parsortix technology with Myriad Genetics’ established diagnostic expertise, the partnership seeks to make genomic insights more accessible, less invasive, and ultimately more impactful for patients worldwide.
If successful, it could redefine how clinicians approach cancer diagnosis and treatment in the years to come.
News Credits: ANGLE partners with Myriad Genetics to explore blood-based cancer testing
Things you may also like: